Adjuvant treatment for premenopausal breast cancer
Part of Cancer, Women’s health & pregnancy clinical trials.
This trial looks back at premenopausal women with early-stage, hormone-positive, HER2-negative breast cancer who had surgery and an Oncotype DX test, to see how different treatments affected their outcomes. If you fit this group, your past medical records could help researchers learn more about the best treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman, premenopausal, and at least 18 years old.
- You have had surgery for early breast cancer, and the cancer is hormone receptor-positive (ER and/or PgR) and HER2-negative.
- Your cancer was in 0 to 3 lymph nodes (pN0 or pN1) and the tumor size was T1, T2, or T3.
- You had an Oncotype DX test done between January 2013 and December 2022, as part of your care.
- Your medical records include details about your treatment, cancer stage, and long-term follow-up (like whether the cancer came back).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks back at treatments given to people with triple-negative or HER2-positive early breast cancer between 2016 and 2021. It aims to understand how treatment approaches have changed over time.
This study tests different treatment plans given before surgery for early breast cancer that is both hormone receptor-positive and HER2-positive. The goal is to see which treatment is more effective and to tailor it to each patient.
This study looks at young women with early-stage breast cancer who are premenopausal (still having periods) and have a low-to-intermediate Oncotype score, to see how well hormone therapy works. It aims to understand if current treatment decisions are appropriate.
This trial studies early, hormone receptor–positive, HER2-negative breast cancer and looks at a group with “high clinical risk” but “low genetic (tumor) risk.” It may help researchers understand which patients may benefit most from treatment decisions guided by genetic tumor testing.
This study observes how doctors treat early breast cancer and what outcomes patients have. It's for people with hormone receptor-positive, HER2-negative breast cancer that hasn't spread to many lymph nodes.
This trial tests if giving hormone-blocking pills before surgery can help guide which treatments you need after surgery. It is for premenopausal women with early-stage, hormone-sensitive breast cancer.
Hear when a new Breast Cancer Early Stage Breast Cancer (Stage 1-3) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.